1027043-84-0

Upstream product

• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 870-46-2 t-butoxycarbonylhydrazine 
• 180002-03-3 C₁₂H₁₇N₃O₄ 
• 179543-91-0 7-chloro-4-oxo-2-(pyrrolidinylcarbonyl)hydroquinoline-3-carboxylic acid 
• 179543-97-6 3-carbomethoxy-2-pyrrolidinocarbamide-7-chloro-4-hydroxyquinoline 
• 170143-35-8 3-carbomethoxy-7-chloro-4-hydroxyquinoline-2-carboxylic acid 
• 349110-82-3 dimethyl 7-chloro-4-hydroxy-quinoline-2,3-dicarboxylate 
• 5900-58-3 2-amino-4-chloro-benzoic acid methyl ester 

Downstream Products

• 349106-02-1 N-{[(3-aminophenyl)methyl][7-chloro-4-oxo-2-(pyrrolidinylcarbonyl)(3-hydroxyquinolyl)]amino}(tert-butoxy)carboxamide 
• 349106-01-0 N-[(tert-butoxy)carbonylamino]-N-[(3-{[(tert-butyl)amino]carbonylamino}-phenyl)methyl][7-chloro-4-oxo-2-(pyrrolidinylcarbonyl)(3-hydroxyquinolyl)]carboxamide 
• 1026616-58-9 C₃₀H₃₅ClN₆O₆ 

Relevant academic research and scientific papers

Pyridazinoquinolinetriones as NMDA glycine-site antagonists with oral antinociceptive activity in a model of neuropathic pain

A series of 7-chloro-2,3-dihydro-2-[1-(pyridinyi)alkyl]-pyridazino[4,5-b] quinoline-1,4,10(5H)-triones were synthesized and found to have potent activity at the glycine site of the NMDA receptor. In some cases, these compounds possessed poor aqueous solubility that may have contributed to poor rat oral bioavailability. Subsequently, compounds have been identified with improved aqueous solubility and oral bioavailability. Several of these compounds were examined in a rat chronic constrictive injury (CCI) model of neuropathic pain and found to have potent activity when dosed orally.